OPKO Health Inc., of Miami, was awarded a grant from the Dravet Syndrome Foundation to support development of potential therapeutics for Dravet syndrome, also called severe myoclonic epilepsy of infancy, a rare genetic disorder that causes a severe form of epilepsy.